P412: LOW EXPOSURE, EXTENDED DOSING MIMICKING CLINICAL EXPOSURES OF ORAL AZACITIDINE SYNERGIZES WITH VENETOCLAX IN PRECLINICAL AML MODELS

• D. Jeyaraju,
• M. Alapa,
• A. Polonskaia,
• A. Risueno Perez,
• R. Hurren,
• X. Wang,
• M. Gronda,
• A. Ahsan,
• C. Wang,
• P. Subramanyam,
• J. Sriganesh,
• A. Anand,
• M. Bysani Reddy,
• K. Ghosh,
• C. Kyriakopoulos,
• N. Lailler,
• C. Hartl,
• D. Lopes de Menezes,
• A. Schimmer,
• P. Hagner,
• A. Gandhi,
• A. Thakurta

Affiliations

D. Jeyaraju

1 Translational Medicine, Bristol Myers Squibb, Summit, United States of America

M. Alapa

1 Translational Medicine, Bristol Myers Squibb, Summit, United States of America

A. Polonskaia

1 Translational Medicine, Bristol Myers Squibb, Summit, United States of America

A. Risueno Perez

2 BMS Center for Innovation and Translational Research Europe, Bristol Myers Squibb, Seville, Spain

R. Hurren

3 Princess Margaret Cancer Center, Toronto, Canada

X. Wang

3 Princess Margaret Cancer Center, Toronto, Canada

M. Gronda

3 Princess Margaret Cancer Center, Toronto, Canada

A. Ahsan

1 Translational Medicine, Bristol Myers Squibb, Summit, United States of America

C. Wang

1 Translational Medicine, Bristol Myers Squibb, Summit, United States of America

P. Subramanyam

4 BBRC

J. Sriganesh

4 BBRC

A. Anand

4 BBRC

M. Bysani Reddy

4 BBRC

K. Ghosh

5 Bristol Myers Squibb, Bangalore, India

C. Kyriakopoulos

2 BMS Center for Innovation and Translational Research Europe, Bristol Myers Squibb, Seville, Spain

N. Lailler

6 Rancho Biosciences, San Diego

C. Hartl

6 Rancho Biosciences, San Diego

D. Lopes de Menezes

7 Bristol Myers Squibb, San Francisco, United States of America

A. Schimmer

3 Princess Margaret Cancer Center, Toronto, Canada

P. Hagner

1 Translational Medicine, Bristol Myers Squibb, Summit, United States of America

A. Gandhi

1 Translational Medicine, Bristol Myers Squibb, Summit, United States of America

A. Thakurta

1 Translational Medicine, Bristol Myers Squibb, Summit, United States of America